LakeShore Biopharma Faces Nasdaq Delisting Over Bid Price Rule Non-Compliance

The latest update is out from LakeShore Biopharma ( (LSB) ).

On September 12, 2025, LakeShore Biopharma announced it received a delisting determination letter from Nasdaq due to non-compliance with the Bid Price Rule, as its share price remained below $1.00 for 30 consecutive business days. The company is not eligible for the standard 180-day compliance period due to a reverse stock split conducted on October 1, 2024. Nasdaq plans to delist the company’s securities unless an appeal is requested by September 18, 2025. LakeShore Biopharma is evaluating its options, including the possibility of appealing the decision.

The most recent analyst rating on (LSB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on LakeShore Biopharma stock, see the LSB Stock Forecast page.

Spark’s Take on LSB Stock

According to Spark, TipRanks’ AI Analyst, LSB is a Neutral.

The overall stock score is primarily influenced by the company’s financial performance challenges, including persistent losses and negative cash flows. Technical analysis indicates a bearish trend, further impacting the score. The lack of valuation metrics such as P/E ratio and dividend yield also contributes to the low score.

To see Spark’s full report on LSB stock, click here.

More about LakeShore Biopharma

LakeShore Biopharma, previously known as YS Biopharma, is a global biopharmaceutical company focused on discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. The company operates in China, Singapore, and the Philippines, and has developed a proprietary PIKA® immunomodulating technology platform targeting diseases such as Rabies, Hepatitis B, and Influenza.

Average Trading Volume: 311,823

Technical Sentiment Signal: Sell

Current Market Cap: $36.16M

For an in-depth examination of LSB stock, go to TipRanks’ Overview page.